---
title: "SION.US (SION.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/SION.US/news.md"
symbol: "SION.US"
name: "SION.US"
parent: "https://longbridge.com/en/quote/SION.US.md"
datetime: "2026-03-03T18:06:14.395Z"
locales:
  - [en](https://longbridge.com/en/quote/SION.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SION.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SION.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/SION.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/SION.US/news.md)


# SION.US (SION.US) — Related News

### [Sionna Therapeutics 10-K: $0 Revenue, $(1.88) EPS](https://longbridge.com/en/news/277462989.md)
*2026-03-02T12:25:01.000Z*
> Sionna Therapeutics reported zero revenue and a net loss per share of $(1.88) for the year, with a total net loss of $(7

### [Sionna Therapeutics reports smaller-than-expected Q4 net loss](https://longbridge.com/en/news/277460974.md)
*2026-03-02T12:11:33.000Z*
> Sionna Therapeutics reported a smaller-than-expected Q4 net loss of $20.44 million, compared to the consensus estimate o

### [Sionna Therapeutics | 8-K: FY2025 Q4 Revenue: USD 0](https://longbridge.com/en/news/277460843.md)
*2026-03-02T12:10:55.000Z*
### [Sionna Therapeutics Maps Mid-2026 CF Catalysts, Highlights NBD1 Stabilizers at Guggenheim Summit](https://longbridge.com/en/news/276001201.md)
*2026-02-15T09:41:12.000Z*
> Sionna Therapeutics presented its strategy for developing next-generation cystic fibrosis therapies focused on NBD1 stab

### [](https://longbridge.com/en/news/275047686.md)
*2026-02-05T23:56:53.000Z*
> The Nasdaq Biotechnology Index fell by 2%. Among the constituent stocks, Jyong Biotech dropped by 20.95%, BridgeBio Phar

### [Sionna Therapeutics (NASDAQ:SION) Trading Down 14.6% Following Insider Selling](https://longbridge.com/en/news/275013513.md)
*2026-02-05T17:50:27.000Z*
> Sionna Therapeutics (NASDAQ:SION) shares fell 14.6% following insider selling by Director Peter A. Thompson, who sold 29

### [OrbiMed Advisors LLC Reports Sale of Sionna Therapeutics Inc. Common Shares](https://longbridge.com/en/news/274890722.md)
*2026-02-05T00:39:52.000Z*
> OrbiMed Advisors LLC has reported the sale of common shares of Sionna Therapeutics Inc. This transaction was documented 

### [Sionna Therapeutics to Present at Guggenheim Securities Emerging Outlook Biotech Summit](https://longbridge.com/en/news/274807253.md)
*2026-02-04T12:00:15.000Z*
> Sionna Therapeutics Inc., a clinical-stage biopharmaceutical company, will present at the Guggenheim Securities Emerging